Расшифровка диагноза с помощьюполяризационной микроскопии после 12 лет существования артрита(описание случая)

1. <div><p>Zhang W., Doherty M., Pascual E. et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1301-11</p><p>Барскова В.Г., Якунина И.А., Ильиных Е.В. и др. Особенности подагры у женщин. Тер арх 2005;4(11):7-13</p><p>Барскова В.Г., Елисеев М.С, Чикаленкова Н.А. Основные факторы полового диморфизма подагры (эстрогены и диуретики по сравнению с алкоголем и генетикой). Тер арх 2011;83(5):57-61.</p><p>Барскова В.Г., Насонова В.А. Дифференциальная диагностика подагрического артрита и методы его купирования. РМЖ 2004;12(6):399-403.</p><p>Zhang W., Doherty M., Bardin T. et al. EULAR recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011;70:563-70.</p><p>Yoo Y., Seo Y.J., Huh M. et al. Gout and coexisting pseudogout in the knee joint. Knee Surg Sports Traumatol Arthrosc 2011;19(4):553-5.</p><p>M.A., Paul H., Abadi I. et al. Multiple microcrystal deposition disease in a patient with systemic lupus erythematosus. Ann Rheum Dis. 1984;43(3):498-502.</p><p>Resnick D., Williams G., Weisman M.H. et al. Rheumatoid arthritis and pseudo-rheumatoid arthritis in calcium pyrophosphate dihy-drate crystal deposition disease. Radiology 1981;140(3):615-21</p><p>Caramaschi P., Biasi D., Carletto A. et al. Calcium pyrophosphate dihydrate crystal deposition disease and primary hyperparathy-roidism associated with rheumatoid arthritis: description of 3 cases. Clin Exp Rheum 2000;18(1):110.</p><p>Барскова В.Г., Насонова В.А., Якунина И.Я. и др. Ретроспективный анализ причин поздней диагностики подагры. Клин геронтол 2004;6:12-7.</p><p>Wallace S.L., Robinson H., Masi A.T. et al. Preliminary critery for the classification of the acute arthritis of gout. Arthr Rheum 1977;20:895-900.</p><p>Pascual E., Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007;66(8):1056-8.</p><p>Aletaha D., Neogi T., Silman A.O. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.</p><p>McCarty D.J. Calcium pyrophosphate crystal deposition disease - 1975. Artr Rheum 1976;19(Suppl.):275-86.</p><p>Puttick M.P., Wade J.P., Chalmers A. et al. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol 1995;22(7):1311-4.</p><p>Kroesen S., Schmid W., Theiler R. Induction of an acute attack of calcium pyrophosphate dihydrate arthritis by intra-articular injection of hylan G-F 20 (Synvisc). Clin Rheum 2000;19(2):147-9.</p><p>Zhang W., Doherty M., Pascual E. et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. Ann Rheum Dis 2011;70:571-5.</p><p>Chollet-Janin A., Finckh A., Dudler J. et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthr Rheum 2007;56(2):688-92.</p><p>Finckh A., Mc Carthy G., Van Linthoudt D. et al. Efficacy of methotrexate in the management of chronic calcium pyrophosphate digydrate (CPPD) arthropathy: an interim analysis of a randomized controlled trial [2010] [SAT0366</p></div><br />